Keratoconjunctivitis sicca is a disorder of the preocular tear film that results in damage to the ocular surface and is associated with symptoms of ocular discomfort. It is also called dry eye, keratitis sicca, sicca syndrome, xerophthalmia, dry eye disease (DED), ocular surface disease (OSD), or dysfunctional tear syndrome (DTS). Keratoconjunctivitis sicca is a Latin word and its literal translation is “dryness of the cornea and conjunctiva.” It may be helpful to know that “Sicca” is part of the English word “desiccate.” The disease in which the eyes do not produce enough tears is also known as “Sjogren’s syndrome”. Cyclosporine is currently the effective and safe therapeutic treatment of dry eye. The objective of this study was to evaluate the prospective effectiveness of cyclosporine nanoparticles for the treatment of keratoconjunctivitis sicca. Cyclosporine associated with the BCS Class II which belongs to immunosuppressive compounds having an anti-inflammatory activity. Arginine is having positive charge which act as a potent vasodilator. Hyaluronic acid is having a negative charge which act as a natural lubricating agent. Therefore, when these are mixed with cyclosporine by ionic-gelation method, it leads to formation of nanoparticles, consequently improve retention time and provide controlled release. Therefore, it will retard the evaporation of water and also improve water holding capacity of eyes. The aim of the proposed study was to develop a controlled release formulation of cyclosporine for the management of keratoconjunctivitis sicca. Therefore, objectives of the proposed study was to formulate cyclosporine nanoparticles for keratoconjunctivitis sicca treatment to achieve control release of cyclosporine from the formulation at the target site and to improve therapeutic outcome.